Keyphrases
Breast Cancer Cell Lines
100%
Gemcitabine
100%
Her2neu
100%
Lung Cancer Cell Lines
100%
Trastuzumab
100%
Protein Expression
27%
Growth Inhibition
27%
Surface Proteins
27%
Synergistic Effect
18%
Immunohistochemistry
18%
Human Lung Cancer Cell Line
18%
Non-small Cell Lung Cancer Cells
18%
Non-small Cell Lung Cancer (NSCLC)
9%
Lung Cancer
9%
Monoclonal Antibody
9%
In Cancer
9%
Breast Cancer Patients
9%
Tumor
9%
Overexpression
9%
Overexpressing
9%
Gene Expression
9%
Cell Surface
9%
Breast Cancer Cells
9%
Cancer Cell Lines
9%
Treatment Effect
9%
Non-small Cell Lung Cancer Patients
9%
Receptor-interacting Protein Kinase 1 (RIPK1)
9%
Breast Cancer
9%
Poor Prognosis
9%
Fluorescence in Situ Hybridization
9%
Patient-assessed
9%
Patients with Breast Cancer
9%
Growth Assay
9%
Combination Index
9%
Additive Effect
9%
Active Agent
9%
Inhibiting Effect
9%
Neu Oncogene
9%
Fluorescence in Situ Hybridization Analysis
9%
Tetrazolium Salts
9%
Breast Cells
9%
Synergy Degree
9%
Oncogene Proteins
9%
Fluorescence Cytometry
9%
Medicine and Dentistry
Gemcitabine
100%
Lung Cancer Cell Line
100%
Trastuzumab
100%
Breast Cancer Cell Line
100%
Non Small Cell Lung Cancer
44%
Breast Cancer
44%
Growth Inhibition
33%
Immunohistochemistry
22%
Small Cell Lung Cancer
22%
Fluorescence in Situ Hybridization
22%
Membrane Protein
22%
Lung Cancer
11%
Neoplasm
11%
Monoclonal Antibody
11%
In Vitro
11%
Cell Surface Protein
11%
Cell Surface
11%
Receptor Protein
11%
Cell Line
11%
Protein Expression
11%
Gene Expression
11%
Treatment Effect
11%
Epidermal Growth Factor Receptor 2
11%
Flow Cytometry
11%
Cancer Cell Line
11%
Oncogene Neu
11%
Tetrazolium
11%
Oncogene Protein
11%
Immunology and Microbiology
Breast Cancer Cell Line
100%
HER2/neu
100%
Lung Cancer Cell Line
100%
Preclinical Study
100%
Trastuzumab
100%
Growth Inhibition
27%
Protein Expression
27%
Cell Surface
18%
Fluorescence in Situ Hybridization
18%
Monoclonal Antibody
9%
Gene Expression
9%
Cell Line
9%
Cancer Cell Line
9%
Oncogene Neu
9%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Preclinical Study
100%
Trastuzumab
100%
HER2/neu
100%
Gemcitabine
100%
Growth Inhibition
27%
Transmembrane Protein
18%
Membrane Protein
18%
Fluorescence in Situ Hybridization
18%
Gene Expression
9%
Protein Expression
9%
Monoclonal Antibody
9%
Cell Surface Protein
9%
Oncogene Neu
9%
Flow Cytometry
9%